Back to the drawing board for Sumitomo’s deal-making
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Bracco’s Blue Earth buy boosts Syncona
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Botox and the value of never-ending profits
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Abbvergan by numbers
2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
A Botox filler for Abbvie's Humira-shaped hole
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Merck and the pitfalls of biopharma success
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
Abbvie proves the best at getting the most out of its workers
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
Array-size deals don’t come around too often
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Rich recognition finally arrives for Array
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.